| Literature DB >> 29620290 |
Go Ninomiya1, Suguru Yamada1, Masamichi Hayashi1, Shigeomi Takeda1, Masaya Suenaga1, Hideki Takami1, Mitsuro Kanda1, Naoki Iwata1, Yukiko Niwa1, Chie Tanaka1, Daisuke Kobayashi1, Tsutomu Fujii1, Goro Nakayama1, Hiroyuki Sugimoto1, Masahiko Koike1, Michitaka Fujiwara1, Yasuhiro Kodera1.
Abstract
In the present study, we investigated the role of lysyl oxidase‑like 2 (LOXL2), the correlation between LOXL2 and epithelial to mesenchymal transition (EMT) and the effects of using β‑aminopropionitrile (BAPN) to inhibit LOXL2 with the aim of reducing tumor progression in hepatocellular carcinoma (HCC). The expression level of LOXL2 was evaluated in HCC and adjacent non‑cancerous tissues using quantitative reverse transcription polymerase chain reaction and clinicopathological analyses. The effects of BAPN on cell proliferation, migration and invasion were investigated in vitro. Additionally, LOXL2 expression was assessed in the culture supernatants of HCC cell lines. Our results revealed that LOXL2 expression was higher in HCC cell lines and tissues. There was a significant correlation between EMT status and LOXL2 levels (P=0.004). BAPN reduced migration and invasion in HCC cells. HCC patients with high levels of LOXL2 expression had relatively shorter disease‑free survival (P=0.009) and overall survival (P=0.035). The expression level of LOXL2 was similar between cell supernatants and HCC cell lines. A multivariate analysis demonstrated that portal vein invasion (P=0.015), venous invasion (P=0.026), serum AFP (α‑fetoprotein) levels (P=0.019) and LOXL2 expression (P=0.009) were independent prognostic factors. Our results indicated that a higher level of LOXL2 may contribute to tumor progression, indicating that LOXL2 has clinical value as a therapeutic target in HCC.Entities:
Mesh:
Substances:
Year: 2018 PMID: 29620290 DOI: 10.3892/or.2018.6349
Source DB: PubMed Journal: Oncol Rep ISSN: 1021-335X Impact factor: 3.906